UP!

DEPO $7.3   View long term graphs

Depomed, Inc.
Type
Public company
Traded as NASDAQ: DEPO
S&P 600 Component
Industry Pharmaceutical Industry
Founded 1995 (1995)
Headquarters Newark, California
Products Pharmaceuticals
Revenue DecreaseUS$342.7 million (2015)
Operating income
DecreaseUS$-50.4 million (2015)
Net income
DecreaseUS$-75.7 million (2015)
Total assets IncreaseUS$1.3 billion (2015)
Total equity DecreaseUS$315 million (2015)
Number of employees
494 (December 2015)
Website www.depomed.com

Depomed, Inc. is an American specialty pharmaceutical company which mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. The company is a publicly traded company on NASDAQ under the symbol "DEPO", with several products approved by the United States Food and Drug Administration (FDA).

The company's products include Nucynta ER, Nucynta, Gralise, Cambia, Lazanda, Zipsor, and DM-1992, which mainly focus on pain, neuropathic pain, and central nervous system diseases.

Nucynta ER, Nucynta IR

On January 15, 2015, Depomed announced the acquisition of the Nucynta franchise from Janssen Pharmaceutica for US$1,050,000,000 in cash. The transaction closed on April 2, 2015, and the products are scheduled to be relaunched in June 2015 after a major salesforce expansion.

Gralise

In January 2011, Gralise once-daily (gabapentin extended release) was approved by the US FDA for the treatment of postherpetic neuralgia. The drug has also received Orphan Drug designation from the FDA.

The company's diabetes treatment, Glumetza (metformin hydrochloride extended release tablet), was approved for the treatment of type II diabetes in adults, and is sold in the US by Valeant.

In June 2012, all rights to Zipsor Liquid Filled Capsules was acquired by Depomed from Xanodyne Pharmaceuticals, revenue generated by Zipsor was approximately US$19,000,000 as within the twelve months from Jun 2011 to May 2012.

In March 2012, the company filed a patent infringement lawsuit against three companies that had filed Abbreviated New Drug Applications with the US FDA, claiming infringement of Depomed's six US patents listed for Gralise in the FDA's Orange Book.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q3 2018 2018-11-05 Future report Set alerts
Q2 2018 2018-08-08 0.19 -0.33
Q1 2018 2018-05-10 0.28 0.48
Q4 2017 2018-02-27 0.15 -0.52
Q3 2017 2017-11-07 0.14 -0.25
Q2 2017 2017-08-07 0.08 -0.43
Q1 2017 2017-05-09 0.07 -0.43
Q4 2016 2017-02-21 0.30 -0.72
Q3 2016 2016-11-07 0.17 -0.21
Q2 2016 2016-08-03 0.19 -0.17

Ratings

2016-07-11 Reiterated Rating Royal Bank Of Canada Hold
2016-07-08 Reiterated Rating Janney Montgomery Scott Buy $28.00
2016-06-26 Reiterated Rating Mizuho Buy
2016-06-22 Reiterated Rating Cantor Fitzgerald Buy
2016-06-15 Reiterated Rating Janney Montgomery Scott Buy $28.00
2016-05-27 Boost Price Target Mizuho Buy $19.00 to $23.00
2016-05-26 Boost Price Target Janney Montgomery Scott Neutral to Hold $20.13 to $28.00
2016-05-17 Reiterated Rating Janney Montgomery Scott Buy $28.00
2016-05-09 Upgrade Mizuho Neutral to Buy $18.00 to $19.00
2016-05-08 Reiterated Rating Cantor Fitzgerald Buy
2016-05-06 Lower Price Target Piper Jaffray Overweight $23.00 to $21.00
2016-05-06 Lower Price Target Piper Jaffray Cos. Overweight $23.00 to $21.00
2016-05-02 Reiterated Rating RBC Capital Sector Perform $22.00
2016-05-02 Reiterated Rating Royal Bank Of Canada Sector Perform $22.00
2016-04-26 Reiterated Rating Cantor Fitzgerald Buy $26.00
2016-04-16 Reiterated Rating Leerink Swann Outperform
2016-04-12 Reiterated Rating Janney Montgomery Scott Buy $28.00
2016-04-11 Boost Price Target Mizuho Neutral $14.00 to $18.00
2016-04-10 Reiterated Rating Cantor Fitzgerald Buy $26.00
2016-04-09 Reiterated Rating Mizuho Neutral $14.00 to $18.00
2016-03-29 Reiterated Rating Cantor Fitzgerald Buy $26.00
2016-03-29 Reiterated Rating Leerink Swann Outperform
2016-03-28 Reiterated Rating Roth Capital Buy
2016-03-25 Lower Price Target RBC Capital $24.00 to $22.00
2016-03-24 Reiterated Rating Piper Jaffray Overweight $23.00
2016-03-24 Initiated Coverage Northland Securities Outperform $22.00
2016-03-24 Lower Price Target Mizuho Neutral $16.00 to $14.00
2016-03-10 Initiated Coverage Leerink Swann Outperform $21.00
2016-03-10 Reiterated Rating Leerink Partner Outperform
2016-02-25 Lower Price Target Mizuho Buy $19.00 to $16.00
2016-02-24 Lower Price Target WallachBeth Capital Buy $33.00 to $27.00
2016-02-23 Reiterated Rating Cantor Fitzgerald Buy $27.00
2016-02-23 Reiterated Rating RBC Capital Sector Perform $26.00 to $24.00
2016-02-22 Reiterated Rating Mizuho Hold $19.00
2016-02-21 Reiterated Rating Piper Jaffray Overweight $23.00
2016-02-09 Reiterated Rating Mizuho Neutral $19.00
2016-02-08 Initiated Coverage Piper Jaffray Overweight $23.00
2016-02-03 Reiterated Rating Cantor Fitzgerald Buy $29.00
2016-01-20 Reiterated Rating Cantor Fitzgerald Buy $29.00
2016-01-07 Initiated Coverage Mizuho Neutral $19.00
2015-12-04 Reiterated Rating Cantor Fitzgerald Buy $29.00
2015-12-03 Initiated Coverage Morgan Stanley Equal to Equal Weight $21.00
2015-11-30 Reiterated Rating Roth Capital Buy $24.00
2015-11-18 Reiterated Rating Janney Montgomery Scott Buy
2015-11-18 Reiterated Rating Cantor Fitzgerald Buy $29.00
2015-11-11 Boost Price Target Roth Capital Buy $21.00 to $24.00
2015-11-11 Upgrade WallachBeth Capital Hold to Buy $33.00
2015-11-10 Reiterated Rating Janney Montgomery Scott Buy $35.00
2015-11-03 Initiated Coverage Cantor Fitzgerald Buy $29.00
2015-10-21 Lower Price Target RBC Capital Sector Perform $32.00 to $26.00
2015-10-20 Reiterated Rating Janney Montgomery Scott Buy $35.00
2015-09-30 Reiterated Rating Roth Capital Buy $33.00 to $21.00
2015-09-01 Reiterated Rating Roth Capital Buy $33.00
2015-07-30 Downgrade Janney Montgomery Scott Buy to Neutral
2015-07-30 Downgrade RBC Capital Outperform to Sector Perform $26.00 to $32.00
2015-07-24 Boost Price Target WallachBeth Capital Hold $26.00 to $33.00
2015-07-14 Boost Price Target Roth Capital Buy $28.50 to $33.00
2015-06-11 Set Price Target Janney Montgomery Scott Buy $25.50 to $26.50
2015-06-11 Initiated Coverage Morgan Stanley Equal to Equal Weight $23.00
2015-05-26 Reiterated Rating Piper Jaffray Overweight $34.00
2015-05-12 Set Price Target Roth Capital Buy to Buy $30.00 to $28.50
2015-05-12 Upgrade Janney Montgomery Scott Neutral to Buy $25.50
2015-05-12 Lower Price Target RBC Capital Outperform $29.00 to $26.00
2015-04-22 Initiated Coverage Piper Jaffray Overweight $37.00
2015-04-06 Boost Price Target Roth Capital Buy $27.00 to $30.00
2015-03-19 Downgrade Janney Montgomery Scott Buy to Neutral $22.00 to $25.50
2015-03-13 Downgrade WallachBeth Capital Buy to Hold $28.00 to $26.00
2015-01-16 Boost Price Target RBC Capital Outperform $20.00 to $22.00
2015-01-16 Upgrade Roth Capital Neutral to Buy $13.50 to $25.00
2014-12-10 Initiated Coverage RBC Capital Outperform $20.00
2014-07-10 Initiated WallachBeth Buy $17
2014-07-10 Initiated Coverage WallachBeth Capital Buy $17.00
2014-05-09 Lower Price Target Roth Capital $14.00 to $13.50
2014-04-04 Boost Price Target Roth Capital $12.50 to $14.00
2014-02-13 Downgrade Roth Capital Buy to Neutral $12.00 to $12.50
2013-12-18 Boost Price Target JMP Securities Outperform $10.00 to $11.00
2013-11-22 Boost Price Target Roth Capital $9.00 to $11.00
2013-10-22 Boost Price Target JMP Securities Market Outperform $9.00 to $10.00
2013-02-25 Downgrade WallachBeth Buy to Hold $8 to $7
2012-01-05 Initiated JMP Securities Mkt Outperform $8
2011-09-30 Initiated Auriga Buy $10
2010-02-18 Downgrade Merriman Buy to Neutral
2009-10-21 Initiated Caris & Company Buy $9
2009-10-12 Reiterated Merriman Buy $11.50 to $7.50
2009-10-05 Initiated Merriman Buy
2008-06-20 Initiated Roth Capital Buy $5
2007-03-15 Reiterated Thomas Weisel Overweight $8 to $6.50
2016-07-11 Reiterated Rating Royal Bank Of Canada Hold
2016-07-08 Reiterated Rating Janney Montgomery Scott Buy $28.00
2016-06-26 Reiterated Rating Mizuho Buy
2016-06-22 Reiterated Rating Cantor Fitzgerald Buy
2016-06-15 Reiterated Rating Janney Montgomery Scott Buy $28.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
STERN JULIAN N 0.36%  (208333) DEPO / FGEN /
STAPLE PETER D 0.20%  (117534) DEPO /
HIGGINS ARTHUR J President and CEO 0.19%  (111760) DEPO / ECL / ENDP / ZMH /
Zenoff David B 0.16%  (93999) DEPO / EXAM /
Moretti August J Chief Financial Officer 0.13%  (74447) ALXA / DEPO /
BURRILL STEVEN 0.07%  (40000) DEPO / TRGT /
Gosling Matthew M VP, General Counsel 0.03%  (19674) DEPO /
Srinivas Rao Chief Medical Officer 0.03%  (19527) DEPO /
DAWES KAREN A 0.02%  (12867) DEPO / PDLI / RGEN /
Sweeney Michael MD VP, Research & Development 0.02%  (9084) DEPO /
Saks Samuel R 0.01%  (5099) ASPX / DEPO / PDLI / TNXP /
ANIDO VICENTE JR 0.01%  (4403) AERI / DEPO /
LAVIGNE LOUIS J JR 0.01%  (4403) AGN / ARAY / DEPO / ZNGA /
Shively Richard Scott Chief Commercial Officer 0.01%  (4290) DEPO / ZGNX /
Cameron Tammy VP, Finance 0.01%  (3960) DEPO /

Comments